Journal
CANCER RESEARCH
Volume 78, Issue 1, Pages 302-308Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-17-1923
Keywords
-
Categories
Funding
- Europe Against Cancer Program of the European Commission (SANCO)
- Deutsche Krebshilfe
- Deutsches Krebsforschungszentrum
- German Federal Ministry of Education and Research
- Danish Cancer Society
- Health Research Fund (FIS) of the Spanish Ministry of Health
- Spanish Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra
- Catalan Institute of Oncology
- Red Tematica de Investigacion Cooperativa en Cancer of the Instituto de Salud Carlos III [ISCIII RTICC RD12/0036/0018]
- FEDER funds/European Regional Development Fund (ERDF)
- Cancer Research UK
- Medical Research Council, United Kingdom
- Greek Ministry of Health
- Stavros Niarchos Foundation
- Hellenic Health Foundation
- Italian Association for Research on Cancer (AIRC)
- Italian National Research Council
- Fondazione-Istituto Banco Napoli, Italy
- Associazione Italiana per la Ricerca sul Cancro (AIRC-Milan)
- Compagnia di San Paolo, Italy
- Dutch Ministry of Public Health, Welfare, and Sports (VWS)
- Netherlands Cancer Registry (NKR)
- LK Research Funds
- Dutch Prevention Funds
- Dutch ZON (Zorg Onderzoek Nederland)
- World Cancer Research Fund (WCRF)
- Statistics Netherlands (the Netherlands)
- Swedish Cancer Society
- Swedish Scientific Council
- Regional Government of Vasterbotten, Sweden
- Norwegian Cancer Society
- Research Council of Norway
- French League against Cancer (LNCC)
- National Institute for Health and Medical Research (INSERM), France
- Mutuelle Generale de l'Education Nationale (MGEN), France
- 3M Co., France
- Gustave Roussy Institute (IGR), France
- General Councils of France
- World Cancer Research Fund
- Foundation to Promote Research into Functional Vitamin B12-Deficiency
- Cancer Research UK [16491] Funding Source: researchfish
Ask authors/readers for more resources
Circulating pyridoxal-5 '-phosphate (PLP) has been linked to lung cancer risk. The PAr index, defined as the ratio 4-pyridoxic acid/(pyridoxal + PLP), reflects increased vitamin B6 catabolism during inflammation. PAr has been defined as a marker of lung cancer risk in a prospective cohort study, but analysis of a larger numbers of cases are needed to deepen the significance of this study. Here, we conducted a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC, n = 521,330), which included 892 incident lung cancer cases and 1,748 controls matched by center, gender, date of blood collection, and date of birth. The association of PAr with risk of lung cancer was evaluated by using conditional logistic regression. Study participants with elevated PAr experienced higher risk of lung cancer in a dose-response fashion, with a doubling in PAr levels associated with 52% higher odds of lung cancer after adjustment for tobacco smoking, serum cotinine levels, educational attainment, and BMI [OR, 1.52; 95% confidence interval (CI) 1.27-1.81; P < 0.001]. Additional adjustment for intake of vegetables and fruits and physical activity did not materially affect risk association. The association of PAr with lung cancer risk was similar in both genders but slightly stronger in former smokers and in participants diagnosed with squamous cell carcinoma. This study provides robust evidence that increased vitamin B6 catabolism is independently associated with a higher risk of future lung cancer. (C) 2017 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available